Athersys, Inc. (NASDAQ:ATHX) Files An 8-K Results of Operations and Financial ConditionItem 2.02.
On August9, 2017, Athersys, Inc. issued a press release announcing financial results for its second quarter ended June30, 2017. A copy of this press release is attached hereto as Exhibit 99.1.
The information contained in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished to the Securities and Exchange Commission and shall not be deemed to be “filed” for the purposes of Section18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section. Furthermore, the information contained in Item 2.02 of this Current Report on Form 8-K shall not be deemed to be incorporated by reference into any registration statement or other document filed to the Securities Act of 1933.
| Item 2.02. | Financial Statements and Exhibits. |
(d) Exhibits.
|
Exhibit No. |
Exhibit Description |
| 99.1 | Press Release dated August9, 2017 |
ATHERSYS, INC / NEW ExhibitEX-99.1 2 d440616dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 ATHERSYS REPORTS SECOND QUARTER 2017 RESULTS Management to host conference call at 4:30pm EDT today CLEVELAND,…To view the full exhibit click here
About Athersys, Inc. (NASDAQ:ATHX)
Athersys, Inc. is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients. In the neurological area, the Company evaluated in a completed Phase II trial, the potential for MultiStem treatment of patients with a history of neurological damage from an ischemic stroke. The Company initiated a Phase II clinical study in the United States for the administration of MultiStem cell therapy to patients with a history of an acute myocardial infarction, or AMI.
